journal article·2023-02-09Open access

Tumor-derived systems as novel biomedical tools—turning the enemy into an ally

Nimeet Desai, Pratik Katare, Vaishali Makwana, Sagar Salave, Lalitkumar K. Vora, Jyotsnendu Giri

Biomaterials Research· Volume 27· Issue 1

Abstract

Cancer is a complex illness that presents significant challenges in its understanding and treatment. The classic definition, "a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body," fails to convey the intricate interaction between the many entities involved in cancer. Recent advancements in the field of cancer research have shed light on the role played by individual cancer cells and the tumor microenvironment as a whole in tumor development and progression. This breakthrough enables the utilization of the tumor and its components as biological tools, opening new possibilities. This article delves deeply into the concept of "tumor-derived systems", an umbrella term for tools sourced from the tumor that aid in combatting it. It includes cancer cell membrane-coated nanoparticles (for tumor theranostics), extracellular vesicles (for tumor diagnosis/therapy), tumor cell lysates (for cancer vaccine development), and engineered cancer cells/organoids (for cancer research). This review seeks to offer a complete overview of the tumor-derived materials that are utilized in cancer research, as well as their current stages of development and implementation. It is aimed primarily at researchers working at the interface of cancer biology and biomedical engineering, and it provides vital insights into this fast-growing topic.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Extracellular vesicles in disease · Phagocytosis and Immune Regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomedical Engineering, Indian Institute of Technology Hyderabad, Kandi, Telangana, India.

Center for Interdisciplinary Programs, Indian Institute of Technology Hyderabad, Kandi, Telangana, India.

Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research-Ahmedabad (NIPER-A), Gujarat, India.

School of Pharmacy, Queen’s University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK.

References (100+)

Show source-provided references
1. 10.1158/2159-8290.CD-21-105910.1158/2159-8290.CD-21-1059 ↗
2. 10.1038/s41392-020-0134-x10.1038/s41392-020-0134-x ↗
3. 10.1002/cncr.3358710.1002/cncr.33587 ↗
4. 10.3322/caac.2166010.3322/caac.21660 ↗
5. 10.3390/cancers1319493110.3390/cancers13194931 ↗
6. 10.1053/j.seminoncol.2019.07.00410.1053/j.seminoncol.2019.07.004 ↗
7. 10.1038/s41392-021-00572-w10.1038/s41392-021-00572-w ↗
8. 10.1002/cncr.2901210.1002/cncr.29012 ↗
9. Vaidyanathan R Soon RH Zhang P Jiang K Lim CT. Cancer diagnosis: from tumor to liquid biopsy and beyond. Lab on a Chip. 2019;19(1):11–34.10.1039/C8LC00684A ↗
10. 10.1016/j.actbio.2023.03.00410.1016/j.actbio.2023.03.004 ↗
11. 10.1007/s10989-018-9728-310.1007/s10989-018-9728-3 ↗
12. 10.1039/C7SC04004K10.1039/C7SC04004K ↗
13. 10.1016/j.bbagen.2011.07.01610.1016/j.bbagen.2011.07.016 ↗
14. Lokeshwar VB Mirza S Jordan A. Targeting hyaluronic acid family for cancer chemoprevention and therapy. Adv Cancer Res. 2014;123:35–65.10.1016/B978-0-12-800092-2.00002-2 ↗
15. 10.1002/cbic.20200036410.1002/cbic.202000364 ↗
16. 10.1038/nrd290910.1038/nrd2909 ↗
17. 10.3390/cancers1103041810.3390/cancers11030418 ↗
18. 10.1016/j.biomaterials.2021.12113710.1016/j.biomaterials.2021.121137 ↗
19. 10.1016/j.jconrel.2011.11.01310.1016/j.jconrel.2011.11.013 ↗
20. 10.1016/j.lfs.2021.11962710.1016/j.lfs.2021.119627 ↗
21. 10.18632/oncotarget.809810.18632/oncotarget.8098 ↗
22. 10.1016/j.apsb.2022.02.02510.1016/j.apsb.2022.02.025 ↗
23. 10.1007/s13346-021-01024-210.1007/s13346-021-01024-2 ↗
24. 10.1016/j.cclet.2022.05.02210.1016/j.cclet.2022.05.022 ↗
25. Patel G Agnihotri TG Gitte M Shinde T Gomte SS Goswami R et al. Exosomes: a potential diagnostic and treatment modality in the quest for counteracting cancer. Cell Oncol. 2023:1–21.10.1007/s13402-023-00810-z ↗
26. 10.1002/adma.20160537510.1002/adma.201605375 ↗
27. 10.1038/s41571-022-00699-x10.1038/s41571-022-00699-x ↗
28. 10.1016/j.addr.2021.11410710.1016/j.addr.2021.114107 ↗
29. Kitaeva KV Rutland CS Rizvanov AA Solovyeva VV. Cell culture based in vitro test systems for anticancer drug screening. Front Bioeng Biotechnol. 2020;8:322.10.3389/fbioe.2020.00322 ↗
30. Falzone L Salomone S Libra M. Evolution of cancer pharmacological treatments at the turn of the third millennium. Front Pharmacol. 2018;9:1300.10.3389/fphar.2018.01300 ↗
31. 10.1016/j.jconrel.2020.12.03410.1016/j.jconrel.2020.12.034 ↗
32. 10.1016/j.msec.2019.01.06610.1016/j.msec.2019.01.066 ↗
33. 10.1038/nbt.333010.1038/nbt.3330 ↗
34. 10.1016/j.addr.2022.11461410.1016/j.addr.2022.114614 ↗
35. 10.1007/s13346-022-01252-010.1007/s13346-022-01252-0 ↗
36. 10.1002/adfm.20190567110.1002/adfm.201905671 ↗
37. 10.1016/j.bioactmat.2021.04.02710.1016/j.bioactmat.2021.04.027 ↗
38. 10.1016/j.cis.2021.10250910.1016/j.cis.2021.102509 ↗
39. 10.1016/j.cell.2020.06.00710.1016/j.cell.2020.06.007 ↗
40. 10.1016/j.biopha.2019.10932010.1016/j.biopha.2019.109320 ↗
41. 10.1074/jbc.REV119.00775910.1074/jbc.REV119.007759 ↗
42. 10.1158/1541-7786.MCR-20-059510.1158/1541-7786.MCR-20-0595 ↗
43. Yu W Yang L Li T Zhang Y. Cadherin signaling in cancer: its functions and role as a therapeutic target. Front Oncol. 2019;9:989.10.3389/fonc.2019.00989 ↗
44. 10.1038/s41568-018-0038-z10.1038/s41568-018-0038-z ↗
45. 10.1093/glycob/cwx10510.1093/glycob/cwx105 ↗
46. 10.1007/s10585-019-09957-210.1007/s10585-019-09957-2 ↗
47. 10.1111/cas.1366310.1111/cas.13663 ↗
48. 10.2147/OTT.S22019610.2147/OTT.S220196 ↗
49. 10.1002/adma.20180788810.1002/adma.201807888 ↗
50. 10.1021/nl500618u10.1021/nl500618u ↗
51. 10.3390/cancers1112183610.3390/cancers11121836 ↗
52. 10.1002/adfm.20210360010.1002/adfm.202103600 ↗
53. Zhang M Cheng S Jin Y Zhang N Wang Y. Membrane engineering of cell membrane biomimetic nanoparticles for nanoscale therapeutics. Clin Transl Med. 2021;11(2):e292.10.1002/ctm2.292 ↗
54. 10.1002/adma.20150608610.1002/adma.201506086 ↗
55. 10.3390/pharmaceutics1506167710.3390/pharmaceutics15061677 ↗
56. 10.1016/j.mtcomm.2022.10428910.1016/j.mtcomm.2022.104289 ↗
57. 10.1038/s41467-021-26052-x10.1038/s41467-021-26052-x ↗
58. 10.1038/s41467-022-33889-310.1038/s41467-022-33889-3 ↗
59. 10.1039/C9BM01392J10.1039/C9BM01392J ↗
60. 10.1016/j.actbio.2020.05.02810.1016/j.actbio.2020.05.028 ↗
61. 10.1002/adma.20160217310.1002/adma.201602173 ↗
62. 10.3390/pharmaceutics1504131310.3390/pharmaceutics15041313 ↗
63. 10.3390/nano1216282610.3390/nano12162826 ↗
64. Cui J Zhang F Yan D Han T Wang L Wang D et al. “Trojan Horse” Phototheranostics: Fine‐Engineering NIR‐II AIEgen Camouflaged by Cancer Cell Membrane for Homologous-Targeting Multimodal Imaging‐Guided Phototherapy. Adv Mater. 2023;35(33):2302639.10.1002/adma.202302639 ↗
65. 10.1016/j.matdes.2022.11081810.1016/j.matdes.2022.110818 ↗
66. 10.1016/j.biomaterials.2022.12144910.1016/j.biomaterials.2022.121449 ↗
67. 10.1016/j.cej.2023.14249510.1016/j.cej.2023.142495 ↗
68. 10.1002/adma.20210788310.1002/adma.202107883 ↗
69. Li Y Zhang H Wang R Wang Y Li R Zhu M et al. Tumor Cell Nanovaccines Based on Genetically Engineered Antibody‐Anchored Membrane. Adv Mater. 2023;35(13):2208923.10.1002/adma.202208923 ↗
70. 10.1002/adma.20210740610.1002/adma.202107406 ↗
71. Wang Z Zhao C Li Y Wang J Hou D Wang L et al. Photostable Cascade Activatable Peptide Self‐assembly on a Cancer Cell Membrane for High‐Performance Identification of Human Bladder Cancer. Adv Mater. 2023:2210732.10.1002/adma.202210732 ↗
72. 10.1002/adma.20190185110.1002/adma.201901851 ↗
73. 10.1002/adhm.20220052110.1002/adhm.202200521 ↗
74. 10.1002/anie.20210228610.1002/anie.202102286 ↗
75. 10.1038/s41565-021-00931-210.1038/s41565-021-00931-2 ↗
76. 10.1021/acs.analchem.8b0091410.1021/acs.analchem.8b00914 ↗
77. 10.1016/j.jddst.2021.10257710.1016/j.jddst.2021.102577 ↗
78. 10.1038/s41580-019-0158-710.1038/s41580-019-0158-7 ↗
79. 10.1038/s41571-018-0036-910.1038/s41571-018-0036-9 ↗
80. 10.1016/j.trecan.2020.09.00310.1016/j.trecan.2020.09.003 ↗
81. 10.1007/s00018-014-1764-310.1007/s00018-014-1764-3 ↗
82. 10.1002/advs.20200350510.1002/advs.202003505 ↗
83. 10.1016/j.semcancer.2021.05.01110.1016/j.semcancer.2021.05.011 ↗
84. De Sousa KP Rossi I Abdullahi M Ramirez MI Stratton D Inal JM. Isolation and characterization of extracellular vesicles and future directions in diagnosis and therapy. Wiley Interdiscip Rev: Nanomed Nanobiotechnol. 2023;15(1):e1835.10.1002/wnan.1835 ↗
85. 10.1016/j.mcpro.2022.10027310.1016/j.mcpro.2022.100273 ↗
86. 10.1080/20013078.2018.153575010.1080/20013078.2018.1535750 ↗
87. 10.1093/nar/gkx89110.1093/nar/gkx891 ↗
88. 10.1016/j.cell.2019.02.01810.1016/j.cell.2019.02.018 ↗
89. 10.1093/nar/gkx85410.1093/nar/gkx854 ↗
90. 10.1038/s12276-019-0218-210.1038/s12276-019-0218-2 ↗
91. Gao Y Qin Y Wan C Sun Y Meng J Huang J et al. Small extracellular vesicles: a novel avenue for cancer management. Front Oncol. 2021;11:638357.10.3389/fonc.2021.638357 ↗
92. 10.1186/s12943-019-0980-810.1186/s12943-019-0980-8 ↗
93. 10.1016/j.bbrc.2017.08.10710.1016/j.bbrc.2017.08.107 ↗
94. 10.1158/1541-7786.MCR-16-016310.1158/1541-7786.MCR-16-0163 ↗
95. 10.18632/oncotarget.1327610.18632/oncotarget.13276 ↗
96. Huang Z, Feng Y. Exosomes derived from hypoxic colorectal cancer cells promote angiogenesis through Wnt4-Induced β-catenin signaling in endothelial cells. Oncol Res Feat Preclin Clin Cancer Ther. 2017;25:651–661.
97. 10.1016/j.ymthe.2018.07.02310.1016/j.ymthe.2018.07.023 ↗
98. 10.1016/j.semcancer.2019.07.02810.1016/j.semcancer.2019.07.028 ↗
99. 10.1002/jcb.2932810.1002/jcb.29328 ↗
100. 10.1038/s41388-020-01425-610.1038/s41388-020-01425-6 ↗